Subtype-specific prognostic impact of Bcl-2 in HER2-positive and HER2-negative breast cancer
Abstract Bcl-2, a key regulator of cellular apoptosis, is typically linked to adverse prognosis in solid tumors due to its inhibition of apoptotic cell death and promotion of cellular proliferation, leading to tumor progression. However, studies on Bcl-2 in breast cancer have shown inconsistent resu...
Saved in:
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Nature Portfolio
2025-01-01
|
| Series: | Scientific Reports |
| Subjects: | |
| Online Access: | https://doi.org/10.1038/s41598-024-83302-w |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1841544735211126784 |
|---|---|
| author | Taeyeong Kim Seung Taek Lim Hyang Suk Choi In-Jeong Cho Hany Noh Jong-In Lee Airi Han |
| author_facet | Taeyeong Kim Seung Taek Lim Hyang Suk Choi In-Jeong Cho Hany Noh Jong-In Lee Airi Han |
| author_sort | Taeyeong Kim |
| collection | DOAJ |
| description | Abstract Bcl-2, a key regulator of cellular apoptosis, is typically linked to adverse prognosis in solid tumors due to its inhibition of apoptotic cell death and promotion of cellular proliferation, leading to tumor progression. However, studies on Bcl-2 in breast cancer have shown inconsistent results, with some indicating favorable outcomes. This study aims to determine the subtype-specific role of Bcl-2 in breast cancer. Female breast cancer patients who completed primary treatment at Wonju Severance Hospital, Korea, from 2004 to 2018 were included. Clinicopathological characteristics, including Bcl-2 expression, were collected, and patients were classified based on Bcl-2 expression in more than or less than 10% of tumor cells. Kaplan–Meier curves compared recurrence-free interval (RFI) and overall survival (OS). The final cohort of 617 patients, with a mean age of 54.79 ± 11.2 years, showed no overall survival difference by Bcl-2 status (p = 0.616). In HER2-overexpressed patients, high Bcl-2 expression was linked to poor prognosis (p = 0.0021). This trend appeared in ER-positive (p = 0.297) and ER-negative (p = 0.029) subgroups. Conversely, in HER2-negative patients, Bcl-2 overexpression indicated better survival (p = 0.009), consistent in ER-positive (p = 0.259) and ER-negative (p = 0.010) subgroups. Bcl-2’s impact on survival varies with HER2 status, showing poor prognosis in HER2-overexpressed and better prognosis in HER2-negative patients. |
| format | Article |
| id | doaj-art-470ff2872a214f5bacfcffda9a2f916e |
| institution | Kabale University |
| issn | 2045-2322 |
| language | English |
| publishDate | 2025-01-01 |
| publisher | Nature Portfolio |
| record_format | Article |
| series | Scientific Reports |
| spelling | doaj-art-470ff2872a214f5bacfcffda9a2f916e2025-01-12T12:20:19ZengNature PortfolioScientific Reports2045-23222025-01-011511810.1038/s41598-024-83302-wSubtype-specific prognostic impact of Bcl-2 in HER2-positive and HER2-negative breast cancerTaeyeong Kim0Seung Taek Lim1Hyang Suk Choi2In-Jeong Cho3Hany Noh4Jong-In Lee5Airi Han6Department of Pathology, Yonsei University Wonju College of MedicineDepartment of Oncology, Yonsei University Wonju College of MedicineDepartment of Surgery, Yonsei University Wonju College of MedicineDepartment of Surgery, Yonsei University Wonju College of MedicineDepartment of Surgery, Yonsei University Wonju College of MedicineDepartment of Oncology, Yonsei University Wonju College of MedicineDepartment of Surgery, Yonsei University Wonju College of MedicineAbstract Bcl-2, a key regulator of cellular apoptosis, is typically linked to adverse prognosis in solid tumors due to its inhibition of apoptotic cell death and promotion of cellular proliferation, leading to tumor progression. However, studies on Bcl-2 in breast cancer have shown inconsistent results, with some indicating favorable outcomes. This study aims to determine the subtype-specific role of Bcl-2 in breast cancer. Female breast cancer patients who completed primary treatment at Wonju Severance Hospital, Korea, from 2004 to 2018 were included. Clinicopathological characteristics, including Bcl-2 expression, were collected, and patients were classified based on Bcl-2 expression in more than or less than 10% of tumor cells. Kaplan–Meier curves compared recurrence-free interval (RFI) and overall survival (OS). The final cohort of 617 patients, with a mean age of 54.79 ± 11.2 years, showed no overall survival difference by Bcl-2 status (p = 0.616). In HER2-overexpressed patients, high Bcl-2 expression was linked to poor prognosis (p = 0.0021). This trend appeared in ER-positive (p = 0.297) and ER-negative (p = 0.029) subgroups. Conversely, in HER2-negative patients, Bcl-2 overexpression indicated better survival (p = 0.009), consistent in ER-positive (p = 0.259) and ER-negative (p = 0.010) subgroups. Bcl-2’s impact on survival varies with HER2 status, showing poor prognosis in HER2-overexpressed and better prognosis in HER2-negative patients.https://doi.org/10.1038/s41598-024-83302-wBcl-2Breast cancerHER2 statusApoptosisPrognosisTumor progression |
| spellingShingle | Taeyeong Kim Seung Taek Lim Hyang Suk Choi In-Jeong Cho Hany Noh Jong-In Lee Airi Han Subtype-specific prognostic impact of Bcl-2 in HER2-positive and HER2-negative breast cancer Scientific Reports Bcl-2 Breast cancer HER2 status Apoptosis Prognosis Tumor progression |
| title | Subtype-specific prognostic impact of Bcl-2 in HER2-positive and HER2-negative breast cancer |
| title_full | Subtype-specific prognostic impact of Bcl-2 in HER2-positive and HER2-negative breast cancer |
| title_fullStr | Subtype-specific prognostic impact of Bcl-2 in HER2-positive and HER2-negative breast cancer |
| title_full_unstemmed | Subtype-specific prognostic impact of Bcl-2 in HER2-positive and HER2-negative breast cancer |
| title_short | Subtype-specific prognostic impact of Bcl-2 in HER2-positive and HER2-negative breast cancer |
| title_sort | subtype specific prognostic impact of bcl 2 in her2 positive and her2 negative breast cancer |
| topic | Bcl-2 Breast cancer HER2 status Apoptosis Prognosis Tumor progression |
| url | https://doi.org/10.1038/s41598-024-83302-w |
| work_keys_str_mv | AT taeyeongkim subtypespecificprognosticimpactofbcl2inher2positiveandher2negativebreastcancer AT seungtaeklim subtypespecificprognosticimpactofbcl2inher2positiveandher2negativebreastcancer AT hyangsukchoi subtypespecificprognosticimpactofbcl2inher2positiveandher2negativebreastcancer AT injeongcho subtypespecificprognosticimpactofbcl2inher2positiveandher2negativebreastcancer AT hanynoh subtypespecificprognosticimpactofbcl2inher2positiveandher2negativebreastcancer AT jonginlee subtypespecificprognosticimpactofbcl2inher2positiveandher2negativebreastcancer AT airihan subtypespecificprognosticimpactofbcl2inher2positiveandher2negativebreastcancer |